Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia

NCT01658956 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

142

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: GCSF administration on days 8 and 12 after chemotherapy

Sponsor

Jules Bordet Institute